LEARNING OBJECTIVES

At the conclusion of our educational meeting, the participant will be able to:

• Acquaint with the new staging and pathology classification systems in lung cancer
• Recognize the clinical significance of molecular genotyping of lung cancer patients
• Understand the molecular pathways that hold promise for therapeutic intervention in lung cancer patients
• Update of Immunotherapy strategies for lung cancer
• Discuss the optimal methodology of evaluation of response in the era of translational research
• Recognize the importance of a multidisciplinary approach to the care lung cancer patients

 

 

TOPICS

• New IASLC lung cancer staging system
• New WHO lung cancer pathology classification
• Neuroendocrine lung cancer update
• Thymic cancer update
• Tumor heterogeneity
• Prognostic and predictive tumor markers
• Molecular signaling of LC
• NSCLC driver oncogenes
• Immunotherapy
• Evaluation of response
• Masterprotocols in lung cancer.
• Agents related-toxicity management
• Newer generation TKIs inhibitors

 

 

 

• Prev